Highlights and Quick Summary
- Share Based Compensation of Revenue for the quarter ending September 30, 2022 was 13.12% (a -12.88% decrease compared to previous quarter)
- Year-over-year quarterly Share Based Compensation of Revenue decreased by -27.19%
- Annual Share Based Compensation of Revenue for 2021 was 22.04% (a -73.46% decrease from previous year)
- Annual Share Based Compensation of Revenue for 2020 was 83.06% (a 128.94% increase from previous year)
- Annual Share Based Compensation of Revenue for 2019 was 36.28% (a -20.25% decrease from previous year)
- Twelve month Share Based Compensation of Revenue ending September 30, 2022 was 15.9% (a -21.05% decrease compared to previous quarter)
- Twelve month trailing Share Based Compensation of Revenue decreased by -27.86% year-over-year
Trailing Share Based Compensation of Revenue for the last four month:
| 30 Sep '22 | 30 Jun '22 | 31 Mar '22 | 31 Dec '21 |
|---|---|---|---|
| 15.9% | 20.14% | 20.61% | 22.04% |
Visit stockrow.com/BCRX
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Share Based Compensation of Revenue of BioCryst Pharmaceuticals, Inc.
Most recent Share Based Compensation of Revenueof BCRX including historical data for past 10 years.Interactive Chart of Share Based Compensation of Revenue of BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. Share Based Compensation of Revenue for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | – | 13.12% | 15.06% | 19.23% | – |
| 2021 | 18.02% | 31.78% | 15.28% | 28.75% | 22.04% |
| 2020 | 146.59% | 47.08% | 114.25% | 57.1% | 83.06% |
| 2019 | 9.28% | 300.23% | 371.89% | 56.34% | 36.28% |
| 2018 | 85.16% | 143.4% | 16.68% | 73.01% | 45.49% |
| 2017 | 59.49% | 63.0% | 75.06% | 26.09% | 50.11% |
| 2016 | 22.36% | 25.6% | 38.56% | 54.88% | 32.21% |
| 2015 | 41.98% | 16.74% | 14.22% | 33.09% | 20.11% |
| 2014 | 66.6% | 43.89% | 240.04% | 46.56% | 74.79% |
| 2013 | 8.41% | 40.1% | 111.94% | 45.08% | 25.2% |
| 2012 | 20.04% | 20.26% | 26.94% | 8.54% | 15.85% |
Business Profile of BioCryst Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology